DK1185294T3 - Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser - Google Patents
Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelserInfo
- Publication number
- DK1185294T3 DK1185294T3 DK00947924T DK00947924T DK1185294T3 DK 1185294 T3 DK1185294 T3 DK 1185294T3 DK 00947924 T DK00947924 T DK 00947924T DK 00947924 T DK00947924 T DK 00947924T DK 1185294 T3 DK1185294 T3 DK 1185294T3
- Authority
- DK
- Denmark
- Prior art keywords
- disorders
- treatment
- interpersonal
- environment
- attenuated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/07—Tetrapeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Radiation-Therapy Devices (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14056399P | 1999-06-23 | 1999-06-23 | |
PCT/EP2000/006259 WO2001000221A2 (en) | 1999-06-23 | 2000-06-22 | Therapeutic methods and compositions for the treatment of impaired interpersonal and behavioral disorders |
EP00947924A EP1185294B1 (en) | 1999-06-23 | 2000-06-22 | Peptides for the treatment of impaired interpersonal and behavioral disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
DK1185294T3 true DK1185294T3 (da) | 2005-08-01 |
Family
ID=22491816
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05006494T DK1593387T3 (da) | 1999-06-23 | 2000-06-22 | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser |
DK00947924T DK1185294T3 (da) | 1999-06-23 | 2000-06-22 | Peptider til behandling af svækkede interpersonelle og adfærdsmæssige lidelser |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK05006494T DK1593387T3 (da) | 1999-06-23 | 2000-06-22 | Sammensætninger for behandling af uhæmmede interpersonelle og adfærdsmæssige forstyrrelser |
Country Status (14)
Country | Link |
---|---|
US (2) | US7387778B2 (da) |
EP (2) | EP1185294B1 (da) |
JP (1) | JP2003512302A (da) |
CN (1) | CN1189211C (da) |
AT (2) | ATE414529T1 (da) |
AU (1) | AU6154700A (da) |
CA (1) | CA2376935A1 (da) |
CY (1) | CY1108745T1 (da) |
DE (2) | DE60019106T2 (da) |
DK (2) | DK1593387T3 (da) |
ES (2) | ES2238299T3 (da) |
NZ (1) | NZ516477A (da) |
PT (2) | PT1185294E (da) |
WO (1) | WO2001000221A2 (da) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
ATE414529T1 (de) | 1999-06-23 | 2008-12-15 | Pasteur Institut | Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
EP1216707B1 (en) * | 2000-12-22 | 2005-02-09 | Institut Pasteur | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
BRPI0407071B8 (pt) | 2003-01-28 | 2021-05-25 | Ironwood Pharmaceuticals Inc | peptídeo purificado, seu método de produção e composição farmacêutica para o tratamento de distúrbios gastrointestinais |
ES2390075T3 (es) | 2004-03-19 | 2012-11-06 | Institut Pasteur | Péptidos derivados de la proteína BPLP humana, polinucleótidos que codifican dichos péptidos y anticuerpos dirigidos contra dichos péptidos |
MX354786B (es) | 2007-06-04 | 2018-03-21 | Synergy Pharmaceuticals Inc | Agonistas de guanilato ciclasa utiles para el tratamiento de trastornos gastrointestinales, inflamacion, cancer y otros trastornos. |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
JP5788788B2 (ja) | 2008-04-07 | 2015-10-07 | アンスティテュ パストゥールInstitut Pasteur | エンケファリンを分解するエクトペプチダーゼを強力に阻害するオピオルフィンペプチド誘導体 |
FR2931362B1 (fr) | 2008-05-26 | 2017-08-18 | Pasteur Institut | L'opiorphine pour une utilisation en tant que psychostimulant. |
ES2627848T3 (es) | 2008-06-04 | 2017-07-31 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
CA2645452A1 (en) * | 2008-11-28 | 2010-05-28 | Institut Pasteur | Use of basic prolin-rich lacrimal gene products, such as opiorphin, as a biomarker |
ES2608050T3 (es) | 2008-12-03 | 2017-04-05 | Synergy Pharmaceuticals Inc. | Formulaciones de agonistas de guanilato ciclasa C y métodos de uso |
DE102009039655B3 (de) | 2009-09-02 | 2011-03-31 | ITT Mfg. Enterprises, Inc., Wilmington | UV-Desinfektionseinrichtung für Abwasser und Trinkwasser mit einer Reinigungsvorrichtung |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CN103764672A (zh) | 2011-03-01 | 2014-04-30 | 辛纳吉制药公司 | 制备鸟苷酸环化酶c激动剂的方法 |
US9486494B2 (en) | 2013-03-15 | 2016-11-08 | Synergy Pharmaceuticals, Inc. | Compositions useful for the treatment of gastrointestinal disorders |
EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
KR102272746B1 (ko) | 2013-06-05 | 2021-07-08 | 보슈 헬스 아일랜드 리미티드 | 구아닐레이트 사이클라제 c의 초순수 작용제, 및 이의 제조 및 사용 방법 |
GB201607814D0 (en) | 2016-05-04 | 2016-06-15 | 5D Health Prot Group Ltd | Anti-microbial compositions |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327966D0 (en) * | 1983-10-19 | 1983-11-23 | Nyegaard & Co As | Chemical compounds |
FR2637600B1 (fr) * | 1988-10-11 | 1992-03-06 | Pasteur Institut | Peptides et polypeptides provenant de la glande sous maxillaire du rat, anticorps monoclonaux et polyclonaux correspondants, hybridomes correspondants et applications de ces produits au diagnostic, a la detection ou a des fins therapeutiques |
US5589189A (en) * | 1994-09-14 | 1996-12-31 | Nexstar Pharmaceuticals, Inc. | Liposome dispersion |
US6589750B2 (en) * | 1997-02-20 | 2003-07-08 | Institut Pasteur | Therapeutic use of the SMR1 protein, the SMR1 maturation products, specifically the QHNPR pentapeptide as well as its biologically active derivatives |
KR100353014B1 (ko) | 1998-11-11 | 2002-09-18 | 동아제약 주식회사 | 발기부전 치료에 효과를 갖는 피라졸로피리미디논 화합물 |
US6455564B1 (en) * | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
ATE414529T1 (de) | 1999-06-23 | 2008-12-15 | Pasteur Institut | Zusammensetzungen zur behandlung von beeinträchtigten zwischenmenschlischen störungen und verhaltenstörungen |
EP1216707B1 (en) | 2000-12-22 | 2005-02-09 | Institut Pasteur | Process for screening ligand molecules that specifically bind to the NEP binding site for the QHNPR pentapeptide |
-
2000
- 2000-06-22 AT AT05006494T patent/ATE414529T1/de active
- 2000-06-22 JP JP2001505930A patent/JP2003512302A/ja active Pending
- 2000-06-22 EP EP00947924A patent/EP1185294B1/en not_active Expired - Lifetime
- 2000-06-22 EP EP05006494A patent/EP1593387B1/en not_active Expired - Lifetime
- 2000-06-22 PT PT00947924T patent/PT1185294E/pt unknown
- 2000-06-22 AT AT00947924T patent/ATE291927T1/de active
- 2000-06-22 AU AU61547/00A patent/AU6154700A/en not_active Abandoned
- 2000-06-22 NZ NZ516477A patent/NZ516477A/xx not_active IP Right Cessation
- 2000-06-22 DK DK05006494T patent/DK1593387T3/da active
- 2000-06-22 ES ES00947924T patent/ES2238299T3/es not_active Expired - Lifetime
- 2000-06-22 ES ES05006494T patent/ES2315753T3/es not_active Expired - Lifetime
- 2000-06-22 DE DE60019106T patent/DE60019106T2/de not_active Expired - Lifetime
- 2000-06-22 PT PT05006494T patent/PT1593387E/pt unknown
- 2000-06-22 CA CA002376935A patent/CA2376935A1/en not_active Abandoned
- 2000-06-22 DK DK00947924T patent/DK1185294T3/da active
- 2000-06-22 WO PCT/EP2000/006259 patent/WO2001000221A2/en active IP Right Grant
- 2000-06-22 DE DE60040878T patent/DE60040878D1/de not_active Expired - Lifetime
- 2000-06-22 CN CNB008092958A patent/CN1189211C/zh not_active Expired - Fee Related
-
2001
- 2001-12-21 US US10/024,535 patent/US7387778B2/en not_active Expired - Fee Related
-
2002
- 2002-12-10 US US10/315,445 patent/US20030186870A1/en not_active Abandoned
-
2009
- 2009-01-16 CY CY20091100058T patent/CY1108745T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
WO2001000221A2 (en) | 2001-01-04 |
WO2001000221A3 (en) | 2001-05-03 |
US7387778B2 (en) | 2008-06-17 |
ATE414529T1 (de) | 2008-12-15 |
EP1593387B1 (en) | 2008-11-19 |
DE60040878D1 (de) | 2009-01-02 |
EP1593387A1 (en) | 2005-11-09 |
JP2003512302A (ja) | 2003-04-02 |
DE60019106D1 (de) | 2005-05-04 |
CN1356906A (zh) | 2002-07-03 |
DK1593387T3 (da) | 2009-03-02 |
PT1185294E (pt) | 2005-08-31 |
US20030078200A1 (en) | 2003-04-24 |
CN1189211C (zh) | 2005-02-16 |
ES2238299T3 (es) | 2005-09-01 |
US20030186870A1 (en) | 2003-10-02 |
ATE291927T1 (de) | 2005-04-15 |
EP1185294A2 (en) | 2002-03-13 |
ES2315753T3 (es) | 2009-04-01 |
CA2376935A1 (en) | 2001-01-04 |
DE60019106T2 (de) | 2006-02-16 |
AU6154700A (en) | 2001-01-31 |
PT1593387E (pt) | 2009-03-18 |
CY1108745T1 (el) | 2014-04-09 |
NZ516477A (en) | 2004-02-27 |
EP1185294B1 (en) | 2005-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1108745T1 (el) | Πεπτιδια δια τη θεραπευτικη αγωγη κακης συμπεριφορας μεταξυ προσωπων | |
TW200510416A (en) | P38 inhibitors and methods of use thereof | |
HRP20020593B1 (en) | Brain, spinal and nerve injury treatment | |
WO2004019884A3 (en) | Agents and methods for enhancing bone formation | |
HK1080467A1 (en) | Benzofuran and benzothiophene derivatives useful in the treatment of hyper-proliferative disorders | |
NO20050851L (no) | Kaspase-inhibitorer og anvendelser derav | |
SE9803710D0 (sv) | Use of certain drugs for treating nerve root injury | |
CY1112238T1 (el) | Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων | |
MY169308A (en) | Treatment of tnf? related disorders | |
DE60327999D1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
ATE325612T1 (de) | Verwendung von hydroxyethylrutosiden zur behandlung von erkältungssymptomen, symptomen der allergischen rhinitis und atemwegsinfektionen | |
ATE430193T1 (de) | Rekombinante alpha-l-iduronidase und behandlung von durch diese hervorgerufene mangelerkrankungen | |
MXPA04001187A (es) | Receptores de interleucina-1 en el tratamiento de enfermedades. | |
WO2005020928A3 (en) | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins | |
MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
DE60008753D1 (de) | Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen | |
ATE541565T1 (de) | Topische verwendung von muskarinischen und opioiden mitteln zur behandlung von tinnitus | |
DE602004028574D1 (de) | Zusammensetzungen und verfahren zur behandlung des reizdarmsyndroms und von nichtulzeröser dyspepsie | |
MXPA06014182A (es) | Nucleosidos de 3-??-d-ribofuranosiltiazolo[4,5-d]piridimina y usos de los mismos. | |
PT1000046E (pt) | Derivados de piperazina activos no trato urinario inferior | |
TR200200278T2 (tr) | Kalsilitik bileşimler | |
DE60142786D1 (de) | Zusammensetzungen und methoden zur behandlung von candidosen | |
MXPA04010816A (es) | Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares. | |
TW200501958A (en) | A therapeutic agent for treating a behavioral disorder | |
DE60321954D1 (de) | Synergistische zusammensetzung enthaltend roflumilast und (r,r)-formoterol |